A quarterly survey by the Federal Reserve Bank of Dallas polls around 140 energy firm executives in Texas, Louisiana, and New Mexico.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
LVMH Moët Hennessy Louis Vuitton acquired Spiza, the parent of high-end Swiss watchmaker L’Epée 1839, on Monday.
Just what, exactly, would Sony and Apollo Global Management be getting out of a Paramount Global acquisition?
Dealmaking-related revenue at a handful of major investment banks collectively rose 27% year-over-year in the first quarter.
The ecommerce titan is pulling out of the $1.4 billion deal, citing difficult antitrust hurdles.
Semiconductor-design software maker Synopsys stepped into the Matrix on Tuesday to acquire Ansys, maker of powerful simulation software.
Twilio CEO and co-founder Jeff Lawson says he’s step down following a protracted battle with a pair of persnickety activist investors.
As 2023 wound to a close, major law firms across the US doled out hefty bonuses and annual raises, according to the Financial Times.
After a lengthy process, the FTC and the DoJ recently released new guidelines for evaluating the legality of mergers and acquisitions.
For the first time in exactly 10 years, Wall Street dealmakers will fall short of facilitating at least $3 trillion worth of deals.
Once the world’s largest corporation, US Steel agreed to sell itself to Japan’s Nippon Steel for just over $14 billion in a deal.
After numerous failed attempts at a friendly merger, Choice Hotels has launched a hostile takeover campaign for Wyndham.
Occidental Petroleum, the oil giant in Berkshire Hathaway’s portfolio, announced it is acquiring CrownRock in a deal worth $12 billion.
Following merger discussions two weeks ago, Humana and Cigna are walking away from what would’ve been the largest deal of the year.
Exxon’s $60 billion planned acquisition of Pioneer Natural Resources has attracted the attention of the Federal Trade Commission.
Roche agreed Monday to acquire anti-obesity drug developer Carmot Therapeutics for an appetizing $3.1 billion.